about
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first ...
Read More
377.35
-5.12
(-1.34%)
2.3M
XNAS Volume
XNAS 11 Sep, 2026 5:30 PM (EDT)
Analyst Downgrade
BMO Capital downgrades Amgen to 'Market Perform'; cites a limited near-term upside potential
See details
Medium Financial Strength
Mid Valuation
Technically Neutral
Mid-range Performer
These stocks have average quality, financial and technical momentum, indicating a mid range performer
View Similar
Embed DVM
Amgen Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..